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background: While second generation drug-eluting stents promote more favorable vascular healing, biodegradable polymer containing stents 
might have a yield in terms of duration of dual antiplatelet therapy (DAPT) than durable polymer stents. We aimed to test whether biolimus-eluting 
stent (BES) with 6-month DAPT would be non-inferior 12-month clinical and angiographic outcome to Zotarolimus-eluting stent (ZES) with 6-month 
DAPT.
Methods: This is a prospective, randomized, open-label, multicenter trial to compare clinical events and angiographic data between BES and ZES 
stents. Currently, 621 patients were randomly assigned. The primary end point was a major adverse cardiac events (MACE) at 12 months. Optical 
coherence tomography (OCT) at 6 month was performed in 30 patients of each group. The primary endpoint was MACE, secondary end points are 
target lesion failure, in-segment late loss (LL) at 12 months, and neointimal hyperplasia (NIH) and uncovered stent strut (USS) by OCT at 6month.
results: Currently, clinical follow-up was available in 325 patients and angiographic follow-up in 311 patients. The primary endpoints were not 
statistically different between the BES and ZES, including MACE (5.5 vs. 6.4%; p =0.76) and stent thrombosis (0.3 vs. 0.3%; p = 0.99). The secondary 
endpoints also were not significantly different between BES and ZES, including target lesion failure (2.0 vs. 1.6%; p = 0.53), in-segment LL (mm) 
at 12 months (0.09±0.37 vs. 0.05±0.39, p =0.61). OCT at 6 month revealed that mean NIH thickness (μm) of BES and ZES were 59.1±30.3, 
54.0±25.6, respectively (p=0.49), and USS percentage (%) of BES and ZES were 20.5±21.8, 17.7±22.4, respectively (p=0.63).
conclusions: BES with biodegradable polymer with 6 month DAPT did not increase the risk of MACE, stent thrombosis, target lesion failure, and LL 
at 12 months comparing with ZES with durable polymer. The 2nd generation DES including BES and ZES are comparably efficacious. Our results need 
to be confirmed in larger trials, and further follow up data.
